positioning immunomodulators as monotherapies or in combination with biologics
Published 7 years ago • 494 plays • Length 21:12Download video MP4
Download video MP3
Similar videos
-
21:14
when and how to use immunomodulators and biologics in ibd
-
21:04
positioning of biologics in the clinic
-
18:03
understanding the contraindications to the use of immunomodulators and biologics for ibd
-
19:03
debate: ibd patient on biologic or immunomodulator who develops a malignancy - may continue meds
-
21:18
how can we prevent and manage the common side effects of immunomodulators and biologics?
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
15:56
therapeutic approaches to ibd in 2020 and beyond
-
4:53
introducing our new physiomimix ht (higher throughput)
-
18:43
neurologic, rheumatologic, and optic complications related to immunomodulators and biologic
-
10:01
debate: immunomodulator monotherapy use in clinical practice - pro
-
5:28
debate: immunomodulator monotherapy use in clinical practice - con
-
18:38
positioning anti-il-12 and anti-il-23 inhibitors
-
21:09
infections due to immunomodulators and/or biologics: identification, prevention and treatment
-
18:39
what are the skin side effects due to immunomodulators and/or biologics?
-
33:34
optimizing the efficacy of immunomodulators and biologics in pediatric ibd
-
21:02
should we change how we position biologics for use in crohn’s disease?
-
17:33
case discussion #1: role of emerging biologics in uc superimposed with anti-tnf-failure
-
18:02
perspectives on immunomodulators and biologics: risk of neoplasia and malignancy development
-
44:08
the evolution of personalized ibd care: navigating mechanisms of biologic therapies
-
10:22
debate: asymptomatic uc patient on an immunomodulator with mucosal inflammation - add biologics
-
19:10
debate: combination or monotherapy with anti-tnf? - monotherapy
-
11:32
debate: ibd patient on biologic or immunomodulator who develops a malignancy - must stop these meds